Home   About this service   Get the news  
+32 2 743 34 03

 Belgium  Other Countries
Page : 1 - 2 - 3 - 4 - 5 - 6 - 7 - 8 - 9 - ...
UCB [BE0003739530/UCB]   
[27/04/2018]

UCB : UCB Media Room: Cimzia CHMP Psoriasis

UCB Announces Positive CHMP Opinion for CIMZIA® certolizumab pegol in Patients with ModeratetoSevere Plaque PsoriasisCIMZIA® certolizumab pegol Phase 3 psoriasis data demonstrated significant and clinically meaningful improvements in biologicnaïve and previously treated patients, with clinical benefit maintained up to one year1This milestone represents UCB’s entry into immunodermatology,... See more
 
UCB [BE0003739530/UCB]   
[26/04/2018]

UCB : UCB Media Room: UCB's General Meeting of Shareholders

UCBs General Meeting of ShareholdersFor financial year 2017:Gross dividend of € 1.18 per share 2.6%, payable 2 May 2018Financial outlook for 2018 confirmedAll agenda items put to vote approvedBrussels Belgium, 26 April 2018 – 18:00 CEST – regulated information Today, UCB held its Annual General Meeting of Shareholders AGM and Extraordinary General Meeting EGM. At the AGM, 145 361 584... See more
 
UCB [BE0003739530/UCB]   
[25/04/2018]

UCB : UCB Media Room: First Three Months Interim Report 2018

UCB First Three Months Interim Report 2018:UCB tracking well towards full year financial outlookBrussels Belgium, 25 April 2018 – 18:00 CEST – regulated information –Revenue reached € 1.07 billion: 5%, 1% CER;adjusted for allergy drug divestiture in 2017: 0%; 4% CERUCB’s main five products reached € 839 million 2%, 8% CERR&D update: Cimzia® available for women with chronic... See more
 
UCB [BE0003739530/UCB]   
[20/04/2018]

UCB : UCB Media Room: UCB acquire the rights to Proximag en’s Midazolam Nasal Spray

UCB to expand epilepsy portfolio with strategic acquisition of Midazolam Nasal Spray from ProximagenMidazolam Nasal Spray USL261, is a nasally administered investigational midazolam formulation intended as a rescue treatment of acute repetitive seizures ARS in patients with epilepsy, which has completed Phase 3 clinical development and is ready to be filed as a New Drug Application NDA in the... See more
 
UCB [BE0003739530/UCB]   
[05/04/2018]

UCB : UCB Media Room: Acquisition of Element Genomics

UCB strengthens research capabilities with acquisition of Element Genomics, a Duke University biotech spinoffAcquisition to strengthen UCB’s genomics and epigenomics research platform to identify novel drug targetsBrussels, Belgium – April 05, 2018 – UCB announces the acquisition of Element Genomics, a smallsize biotech spinoff from Duke University, based in Durham, North Carolina USA. The... See more